Tannic Acid

Summary

Tannic Acid (CHEMBL506247) is an approved unknown targeting ANO1; indicated across 1 condition including gastroenteritis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Targets: 1 (ANO1)
• Indications: 1 condition
• Clinical trials: 1
• Chemistry: 1701.2 Da · C76H52O46

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL506247
Name	Tannic Acid
Type	Unknown
Max phase	4
FDA approved	yes
PubChem CID	16129778
Molecular formula	C76H52O46
Molecular weight	1701.2
InChIKey	LRBQNJMCXXYXIU-PPKXGCFTSA-N

SMILES: C1=C(C=C(C(=C1O)O)O)C(=O)OC2=CC(=CC(=C2O)O)C(=O)OC[C@@H]3[C@H]([C@@H]([C@H]([C@@H](O3)OC(=O)C4=CC(=C(C(=C4)OC(=O)C5=CC(=C(C(=C5)O)O)O)O)O)OC(=O)C6=CC(=C(C(=C6)OC(=O)C7=CC(=C(C(=C7)O)O)O)O)O)OC(=O)C8=CC(=C(C(=C8)OC(=O)C9=CC(=C(C(=C9)O)O)O)O)O)OC(=O)C1=CC(=C(C(=C1)OC(=O)C1=CC(=C(C(=C1)O)O)O)O)O

IUPAC name: [2,3-dihydroxy-5-[[(2R,3R,4S,5R,6S)-3,4,5,6-tetrakis[[3,4-dihydroxy-5-(3,4,5-trihydroxybenzoyl)oxybenzoyl]oxy]oxan-2-yl]methoxycarbonyl]phenyl] 3,4,5-trihydroxybenzoate

Also known as: Asian holly oak nutgall, E181, FEMA NO. 3042, Gallotannic acid, Gallotannin, NSC-656273, NSC-758670, Tannic acid, Tannic acid component of depinar, Tannic acid component of oc-108, unspecified, Tannicum acidum

Patent coverage: 15,582 distinct patent families (25,753 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 25,712 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ANO1	CaCC	Inhibition		1.2%	Q5XXA6

Broader ChEMBL bioactivity targets: 27 (assay-derived). Sample: Lethal(3)malignant brain tumor-like protein 1, Ubiquitin carboxyl-terminal hydrolase 2, Solute carrier organic anion transporter family member 1B1, Solute carrier organic anion transporter family member 1B3, Transmembrane protease serine 2, cGMP-specific 3’,5’-cyclic phosphodiesterase, Thromboxane-A synthase, Tyrosine-protein kinase Fyn, Leukotriene C4 synthase, Beta-lactamase, Carbonic anhydrase 2, Tyrosine-protein kinase Lck, Mitogen-activated protein kinase 14, Carbonic anhydrase 1, Aldo-keto reductase family 1 member B1, Carbonic anhydrase 6, Cytochrome P450 1A2, Mitogen-activated protein kinase 3, Cytochrome P450 2C9, Replicase polyprotein 1a.

Bioactivity

ChEMBL activities: 28 potent at pChembl ≥ 5 of 33 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FYN	7.66	IC50	22	nM	CHEMBL_ACT_7808146
LCK	7.1	IC50	79	nM	CHEMBL_ACT_7808150
L3MBTL1	7	Potency	100	nM	CHEMBL_ACT_4622354
P29990	6.89	IC50	130	nM	CHEMBL_ACT_24666550
P29990	6.89	IC50	130	nM	CHEMBL_ACT_24666553
P29990	6.89	IC50	130	nM	CHEMBL_ACT_24666554
P29990	6.89	IC50	130	nM	CHEMBL_ACT_24666608
MAPK1	6.73	IC50	185	nM	CHEMBL_ACT_7808138
P12530	6.57	IC50	268	nM	CHEMBL_ACT_7806079
TBXAS1	6.49	IC50	325	nM	CHEMBL_ACT_7808186
P07943	6.46	IC50	346	nM	CHEMBL_ACT_7805973
MAPK14	6.43	IC50	375	nM	CHEMBL_ACT_7808140
P0DTD1	6.23	EC50	585	nM	CHEMBL_ACT_25516540
P00811	6.15	Potency	707.9	nM	CHEMBL_ACT_4653660
CYP1A2	6.04	IC50	919	nM	CHEMBL_ACT_7806013
SLCO1B1	5.84	Ki	1460	nM	CHEMBL_ACT_13800664
TMPRSS2	5.64	IC50	2310	nM	CHEMBL_ACT_25847331
SLCO1B1	5.58	IC50	2630	nM	CHEMBL_ACT_13800600
A6XA80	5.57	IC50	2715	nM	CHEMBL_ACT_7806075
HMGCR	5.5	IC50	3127	nM	CHEMBL_ACT_7806065
SLCO1B3	5.49	Ki	3230	nM	CHEMBL_ACT_13798665
HSPD1	5.42	IC50	3800	nM	CHEMBL_ACT_19209387
MAPK3	5.39	IC50	4052	nM	CHEMBL_ACT_7808136
SLCO1B3	5.38	IC50	4169	nM	CHEMBL_ACT_13798601
CYP2C9	5.34	IC50	4607	nM	CHEMBL_ACT_7806019
PDE5A	5.33	IC50	4703	nM	CHEMBL_ACT_7808110
USP2	5.3	Potency	5012	nM	CHEMBL_ACT_3608048
P0C6U8	5.08	EC50	8307	nM	CHEMBL_ACT_25516541

Target pathways

Aggregated over 1 target gene(s): ANO1.

Top Reactome pathways

10 total, by targets touching each:

Pathway	Targets	Genes
Disease	1	ANO1
Stimuli-sensing channels	1	ANO1
Transport of small molecules	1	ANO1
Infectious disease	1	ANO1
SARS-CoV Infections	1	ANO1
SARS-CoV-2 Infection	1	ANO1
Induction of Cell-Cell Fusion	1	ANO1
Late SARS-CoV-2 Infection Events	1	ANO1
Viral Infection Pathways	1	ANO1
Ion channel transport	1	ANO1

Dominant GO biological processes

GO term	Targets
chloride transport	1
phospholipase C-activating G protein-coupled receptor signaling pathway	1
iodide transport	1
monoatomic ion transmembrane transport	1
cellular response to heat	1
detection of temperature stimulus involved in sensory perception of pain	1
mucus secretion	1
protein localization to membrane	1
glial cell projection elongation	1
cellular response to peptide	1
chloride transmembrane transport	1
monoatomic ion transport	1
monoatomic cation transmembrane transport	1

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
gastroenteritis	3	MONDO:0002269	EFO:1001463

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00521703	PHASE3	COMPLETED	Evaluation of Topical Lidocaine Spray as Adjuvant to Upper Gastrointestinal Endoscopy in Children

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

2 molecules share ≥1 primary target. Top 2 by shared-target count:

Molecule	Source	Status	Shared targets
NITAZOXANIDE	ChEMBL + PubChem	Phase 4 (approved)	ANO1
NICLOSAMIDE	ChEMBL	Phase 4 (approved)	ANO1